Pfizer Inc (PFE)

$27.12 +0.36 (1.35%)
Market Cap 152.52B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 8.59
Forward PE 8.81
Profit Margin 12.42%
Debt to Equity Ratio 0.71
Volume 26,992,171
Avg Vol 44,104,156
Day's Range N/A - N/A
Shares Out 5.70B
Stochastic %K 100%
Beta 0.34
Analysts Sell
Price Target $28.60

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
EmbraceVolatility
EmbraceVolatility Aug. 10 at 5:10 PM
$PFE Blowing past all resistances. Happy, but NGL, they trained me to expect a rug pull.
0 · Reply
ProTraderColin
ProTraderColin Aug. 10 at 4:51 PM
$PFE a break of 27.79 would bring it to MULTI YEAR highs
1 · Reply
dom04
dom04 Aug. 10 at 3:56 PM
$PFE if 27$ fail, 26$ coming before next leg up!
0 · Reply
LongStrongDong
LongStrongDong Aug. 10 at 3:32 PM
$PFE he he he he! Up we go
0 · Reply
CandlesBACKEDSECURITIES
CandlesBACKEDSECURITIES Aug. 10 at 3:17 PM
$PFE we trust the stock
1 · Reply
CandlesBACKEDSECURITIES
CandlesBACKEDSECURITIES Aug. 10 at 3:17 PM
$PFE perfect entry
0 · Reply
STOCKPICKERTRADER
STOCKPICKERTRADER Aug. 10 at 3:16 PM
$PFE Trading Central upgrades Pfizer from SELL to BUY. INVESTARS ANALYST ACTIONS - PUBLIC Aug-08-2026 3:20 p.m. ET On August 8, 2026 Trading Central upgraded Pfizer (PFE) from SELL to BUY.
0 · Reply
Micheal_Pothead
Micheal_Pothead Aug. 10 at 3:15 PM
$PFE covered calls may have been a mistake lol
1 · Reply
Makingmillions192
Makingmillions192 Aug. 10 at 3:14 PM
$LEXX Big Pharma is actively spending billions to secure oral GLP-1 delivery platforms: Novo Nordisk & Vivtex: Signed an up to $2.1B licensing deal to use Vivtex’s oral delivery tech for next-gen obesity pills. Roche & Gasherbrum Bio: Paid $100M upfront to secure non-exclusive patent rights for oral GLP-1 formulation IP. Pfizer & Metsera: Closed a multi-billion-dollar transaction to acquire advanced oral metabolic therapies. These transactions demonstrate that Big Pharma is actively deploying capital into oral delivery technologies. Big Pharma owns the multi-billion-dollar GLP-1 molecules, but specialized small/micro-cap platform companies own the proprietary delivery mechanisms needed to solve stomach degradation, improve bioavailability, and reduce severe GI side effects. Lexaria is next 🔥 $PFE $RHHBY $NVO $LLY
0 · Reply
INEEDMONEY87
INEEDMONEY87 Aug. 10 at 2:51 PM
$PFE wow really turned here, nice..... now wheres the rug pull?
1 · Reply
Latest News on PFE
Pfizer price target lowered to $31 from $35 at Guggenheim

2026-08-07T11:40:49.000Z - 3 days ago

Pfizer price target lowered to $31 from $35 at Guggenheim

Pfizer’s (PFE) Q2 Earnings Support a Bullish View

2026-08-06T13:09:00.000Z - 4 days ago

Pfizer’s (PFE) Q2 Earnings Support a Bullish View

Pfizer price target raised to $27 from $26 at BofA

2026-08-05T10:45:23.000Z - 5 days ago

Pfizer price target raised to $27 from $26 at BofA

Pfizer Earnings Call Transcript: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 6 days ago

Pfizer Earnings Call Transcript: Q2 2026

Pfizer Earnings release: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 6 days ago

Pfizer Earnings release: Q2 2026

Pfizer Slides: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 6 days ago

Pfizer Slides: Q2 2026

Pfizer Quarterly report: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 6 days ago

Pfizer Quarterly report: Q2 2026

Pfizer Stock (PFE) Falls on 2026 Sales Outlook as Cancer Drugs Fuel Q2 Beat

2026-08-04T11:39:45.000Z - 6 days ago

Pfizer Stock (PFE) Falls on 2026 Sales Outlook as Cancer Drugs Fuel Q2 Beat

Pfizer Post Loss on Higher Revenue

Aug 4, 2026, 7:24 AM EDT - 6 days ago

Pfizer Post Loss on Higher Revenue

Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products

Aug 4, 2026, 7:13 AM EDT - 6 days ago

Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products

Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings

Aug 4, 2026, 7:12 AM EDT - 6 days ago

Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings

BNTX

Pfizer reports Q2 adjusted EPS 77c, consensus 68c

2026-08-04T10:52:17.000Z - 6 days ago

Pfizer reports Q2 adjusted EPS 77c, consensus 68c

Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis

Aug 4, 2026, 6:52 AM EDT - 6 days ago

Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis

Pfizer backs FY26 adjusted EPS view $2.80-$3.00, consensus $2.95

2026-08-04T10:51:36.000Z - 6 days ago

Pfizer backs FY26 adjusted EPS view $2.80-$3.00, consensus $2.95

Pfizer announces expansion of productivity enhancement Initiatives

2026-08-04T10:50:31.000Z - 6 days ago

Pfizer announces expansion of productivity enhancement Initiatives

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

Aug 4, 2026, 6:45 AM EDT - 6 days ago

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

5 Things to Know Before the Stock Market Opens on Monday

Aug 3, 2026, 8:10 AM EDT - 7 days ago

5 Things to Know Before the Stock Market Opens on Monday

AMD AZN BMY CAT CVS DASH DIS

Pfizer's oral drug restores skin pigmentation in late-stage vitiligo trials

Jul 30, 2026, 7:48 AM EDT - 11 days ago

Pfizer's oral drug restores skin pigmentation in late-stage vitiligo trials

Pfizer says LITFULO studies meet co-primary endpoints

2026-07-30T11:03:18.000Z - 11 days ago

Pfizer says LITFULO studies meet co-primary endpoints

Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo

Jul 30, 2026, 6:45 AM EDT - 11 days ago

Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo

EC authorizes Pfizer, BioNTech XFG-adapted COVID-19 vaccine in EU

2026-07-29T20:42:19.000Z - 11 days ago

EC authorizes Pfizer, BioNTech XFG-adapted COVID-19 vaccine in EU

BNTX

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

Jul 29, 2026, 4:30 PM EDT - 11 days ago

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

BNTX

Pfizer's prostate cancer drug combination gets US FDA priority review

Jul 22, 2026, 4:48 PM EDT - 18 days ago

Pfizer's prostate cancer drug combination gets US FDA priority review

FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

Jul 22, 2026, 4:30 PM EDT - 18 days ago

FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

Trump says generic drugs to face no US tariffs for 2 years before rates of 100% and 200% later

Jul 21, 2026, 7:10 PM EDT - 19 days ago

Trump says generic drugs to face no US tariffs for 2 years before rates of 100% and 200% later

LLY

Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

Jul 16, 2026, 1:39 PM EDT - 24 days ago

Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Jul 10, 2026, 11:23 AM EDT - 4 weeks ago

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

Jul 6, 2026, 10:00 AM EDT - 5 weeks ago

Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.

Jun 29, 2026, 4:43 PM EDT - 5 weeks ago

Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.

ABT ADM APD BAC CMCSA CVS DIS

Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review

Jun 29, 2026, 1:20 AM EDT - 6 weeks ago

Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review

Pfizer Declares Third-Quarter 2026 Dividend

Jun 24, 2026, 3:52 PM EDT - 6 weeks ago

Pfizer Declares Third-Quarter 2026 Dividend

FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

Jun 24, 2026, 2:10 PM EDT - 6 weeks ago

FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

Pfizer dismissed from US states' drug price-fixing lawsuit

Jun 24, 2026, 10:51 AM EDT - 6 weeks ago

Pfizer dismissed from US states' drug price-fixing lawsuit

China outpacing Europe in drug innovation and development, Pfizer executive says

Jun 23, 2026, 12:10 PM EDT - 6 weeks ago

China outpacing Europe in drug innovation and development, Pfizer executive says

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

Jun 23, 2026, 10:00 AM EDT - 6 weeks ago

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

Pfizer's experimental drug misses main goal of lung cancer trial

Jun 22, 2026, 4:43 PM EDT - 6 weeks ago

Pfizer's experimental drug misses main goal of lung cancer trial

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Jun 22, 2026, 4:30 PM EDT - 6 weeks ago

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Wall Street loves growth stocks — but these 10 ‘losers' are primed to win

Jun 22, 2026, 2:32 PM EDT - 6 weeks ago

Wall Street loves growth stocks — but these 10 ‘losers' are primed to win

ACHR AGCO COF DHI DVN EOG TSN

Pfizer CFO Dave Denton to step down, leave company in August

Jun 18, 2026, 6:52 AM EDT - 7 weeks ago

Pfizer CFO Dave Denton to step down, leave company in August

Pfizer Announces Chief Financial Officer Transition

Jun 18, 2026, 6:45 AM EDT - 7 weeks ago

Pfizer Announces Chief Financial Officer Transition

Pfizer CEO warns German investment at risk over drug pricing policies

Jun 10, 2026, 7:56 AM EDT - 2 months ago

Pfizer CEO warns German investment at risk over drug pricing policies

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

Jun 9, 2026, 2:07 PM EDT - 2 months ago

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

DG ALGN BBY BIIB CVS VZ

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Jun 9, 2026, 9:20 AM EDT - 2 months ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN JNJ LLY MRK NVO

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

Jun 9, 2026, 3:20 AM EDT - 2 months ago

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

BMY LLY MRK RDW UTHR XBI

Pfizer Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Pfizer Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

US FDA approves Pfizer's bleeding disorder drug for children

Jun 8, 2026, 6:49 AM EDT - 2 months ago

US FDA approves Pfizer's bleeding disorder drug for children

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

Jun 8, 2026, 6:45 AM EDT - 2 months ago

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Transcript: Study update

Pfizer Slides: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Slides: Study update

Pfizer Press release: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Press release: Study update

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Jun 6, 2026, 9:06 AM EDT - 2 months ago

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

Jun 6, 2026, 9:00 AM EDT - 2 months ago

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI

Jun 4, 2026, 10:00 AM EDT - 2 months ago

Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

Jun 4, 2026, 6:40 AM EDT - 2 months ago

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

LLY

Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 2:00 PM EDT - 2 months ago

Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Jun 1, 2026, 10:00 AM EDT - 2 months ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

May 31, 2026, 8:00 AM EDT - 2 months ago

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

May 30, 2026, 8:00 AM EDT - 2 months ago

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

May 29, 2026, 8:00 AM EDT - 2 months ago

Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

May 28, 2026, 11:10 PM EDT - 2 months ago

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal

May 28, 2026, 7:19 PM EDT - 2 months ago

China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 28, 2026, 7:00 PM EDT - 2 months ago

Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

May 28, 2026, 7:00 PM EDT - 2 months ago

Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

May 27, 2026, 10:00 AM EDT - 2 months ago

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

May 20, 2026, 9:00 AM EDT - 2 months ago

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial

May 20, 2026, 5:08 AM EDT - 2 months ago

Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

May 20, 2026, 5:05 AM EDT - 2 months ago

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

EmbraceVolatility
EmbraceVolatility Aug. 10 at 5:10 PM
$PFE Blowing past all resistances. Happy, but NGL, they trained me to expect a rug pull.
0 · Reply
ProTraderColin
ProTraderColin Aug. 10 at 4:51 PM
$PFE a break of 27.79 would bring it to MULTI YEAR highs
1 · Reply
dom04
dom04 Aug. 10 at 3:56 PM
$PFE if 27$ fail, 26$ coming before next leg up!
0 · Reply
LongStrongDong
LongStrongDong Aug. 10 at 3:32 PM
$PFE he he he he! Up we go
0 · Reply
CandlesBACKEDSECURITIES
CandlesBACKEDSECURITIES Aug. 10 at 3:17 PM
$PFE we trust the stock
1 · Reply
CandlesBACKEDSECURITIES
CandlesBACKEDSECURITIES Aug. 10 at 3:17 PM
$PFE perfect entry
0 · Reply
STOCKPICKERTRADER
STOCKPICKERTRADER Aug. 10 at 3:16 PM
$PFE Trading Central upgrades Pfizer from SELL to BUY. INVESTARS ANALYST ACTIONS - PUBLIC Aug-08-2026 3:20 p.m. ET On August 8, 2026 Trading Central upgraded Pfizer (PFE) from SELL to BUY.
0 · Reply
Micheal_Pothead
Micheal_Pothead Aug. 10 at 3:15 PM
$PFE covered calls may have been a mistake lol
1 · Reply
Makingmillions192
Makingmillions192 Aug. 10 at 3:14 PM
$LEXX Big Pharma is actively spending billions to secure oral GLP-1 delivery platforms: Novo Nordisk & Vivtex: Signed an up to $2.1B licensing deal to use Vivtex’s oral delivery tech for next-gen obesity pills. Roche & Gasherbrum Bio: Paid $100M upfront to secure non-exclusive patent rights for oral GLP-1 formulation IP. Pfizer & Metsera: Closed a multi-billion-dollar transaction to acquire advanced oral metabolic therapies. These transactions demonstrate that Big Pharma is actively deploying capital into oral delivery technologies. Big Pharma owns the multi-billion-dollar GLP-1 molecules, but specialized small/micro-cap platform companies own the proprietary delivery mechanisms needed to solve stomach degradation, improve bioavailability, and reduce severe GI side effects. Lexaria is next 🔥 $PFE $RHHBY $NVO $LLY
0 · Reply
INEEDMONEY87
INEEDMONEY87 Aug. 10 at 2:51 PM
$PFE wow really turned here, nice..... now wheres the rug pull?
1 · Reply
taxplanr
taxplanr Aug. 10 at 2:29 PM
HCQ helps viruses target cancer cells $MRNA $BNTX $PFE $MRK https://www.instagram.com/reel/DbzsTZFsueC/?igsh=dnM5ZDJkb2FqZ2Nl
0 · Reply
Yonia
Yonia Aug. 10 at 2:14 PM
$PFE $SPY starts to pump and pfe will dump like usual 😂.
0 · Reply
TheUnmaker
TheUnmaker Aug. 10 at 2:08 PM
$TNXP Break $14.15 and we go back over $16 this week. $PFE $SLS $JNJ $GRAL
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 10 at 1:56 PM
$PFE POS is cooking lately...
0 · Reply
ProTraderColin
ProTraderColin Aug. 10 at 1:55 PM
$PFE wow this lame duck is setting up nicely!
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Aug. 10 at 1:55 PM
$PFE - Gawd dayum Pfizzy
0 · Reply
La_Parka3
La_Parka3 Aug. 10 at 1:50 PM
$MRNA $PFE $JNJ The mandates of pandemic past continue to haunt the shorts as they still use it as their excuse to explain away why vaccines continue to sell when the mandates had been cancelled completely several years ago.
0 · Reply
Micheal_Pothead
Micheal_Pothead Aug. 10 at 1:49 PM
$PFE a lot of 26.50 calls this week
0 · Reply
simonds
simonds Aug. 10 at 1:48 PM
$PFE Wants to go to $60 plus.
0 · Reply
JodieChristy
JodieChristy Aug. 10 at 1:28 PM
BREAKING NEWS! $NVO allies with AWS to launch a London AI hub, supercharging AI drug discovery! Pharma x Tech Giants: $NVO $AMZN $GOOGL $LLY $PFE Compressing timelines from drug target to clinical trial this AI healthcare revolution is locked in! Just posted my dark pool order flow tracking, institutional buy zones, and full trade plan for these 5 tickers on my profile. Check the main page for the complete setup and smash follow to ride the wave together!
0 · Reply
INEEDMONEY87
INEEDMONEY87 Aug. 10 at 12:45 PM
$PFE boo i want the quarter back!!!
1 · Reply
Lowkeyoptions
Lowkeyoptions Aug. 10 at 12:10 PM
$RGC $MRK $PFE $MRNA $KPTI
0 · Reply